ABSTRACT
Objective To investigate the change and clinical significance of growth differentiation factor 15 (GDF15) and gastric cancer antigen 724 (CA724) in serum of patients with gastric cancer .Methods Serum levels of GDF15 in serum of 30 patients with gastric cancer were detected by ELISA .The levels of serum gas-tric CA724 were measured by electrochemiluminescence ,and 32 cases of benign gastric lesions and 30 healthy controls were compared .Results The levels of serum GDF15 and CA724 in patients with gastric cancer were (1 .58 ± 0 .53)ng/mL and (40 .80 ± 5 .20) IU/mL ,respectively .The levels of serum GDF15 and CA724 in pa-tients with benign gastric lesions were (0 .26 ± 0 .11) ng/mL ,(12 .90 ± 2 .30) IU/mL (P<0 .01) .The levels of GDF15 and CA724 in normal control group were (0 .17 ± 0 .08)ng/mL and (3 .80 ± 0 .90)IU/mL respectively . The levels of serum GDF15 and CA724 in gastric cancer group were significantly higher than those in benign gastric lesions and normal control group (P<0 .01) .The level of serum GDF15 was closely related to tumor size ,TNM stage and lymph node metastasis (P<0 .05) .The sensitivity of gastric cancer was 83 .3％ ,the spe-cificity was 83 .9％ and the AUC was 0 .837 .The sensitivity of CA724 was 90 .0％ ,the specificity was 76 .5％and the AUC was 0 .886 .The combined detection of AUC was 0 .920 ,which was significantly higher than that of single detection .Conclusion GDF15 is associated with the development and progression of gastric cancer .Combined detection of GDF15 and CA724 in serum is helpful for early diagnosis of gastric cancer and progno-sis .